BIO

Business Context and Reporting Period

Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 64% of sales are international, creating exposure to currency fluctuations.

Key Financial Metrics

Note: Total Debt calculated as Notes payable/current maturities ($9,658) + Long-term debt ($425,807).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.9% year-over-year. On a currency-neutral basis, sales grew 10.2%, driven by a 14.9% growth in the Life Science segment and 5.5% growth in Clinical Diagnostics.
• Profitability: Net income increased 52.4% to $33.5 million. This was significantly aided by a $4.0 million gain on the divestiture of discontinued operations (confocal microscopy line) and a lower effective tax rate (22.5% vs. 28.2% in Q1 2004).
• Margins: Consolidated gross margin decreased 120 basis points to 55.6%. The Life Science segment margin declined due to lower average selling prices for BSE tests and increased amortization from the MJ GeneWorks acquisition.
• Interest Expense: Increased by $3.1 million to $8.1 million due to higher average indebtedness ($436 million vs. $237 million in Q1 2004), reflecting the issuance of $200 million in Senior Subordinated Notes in December 2004.
• Liquidity: Cash and cash equivalents surged to $317.9 million from $195.7 million at year-end 2004, driven by strong investing cash flows from the sale of marketable securities.

Outlook, Risks, and Contingencies

Management Commentary and Guidance

Management notes that the Life Science market is growing at approximately 5% (currency neutral), while the Clinical Diagnostics market is growing at 3%. Pricing pressures exist in routine diagnostic tests due to declining government reimbursements. The company is actively reviewing potential acquisitions to expand both segments.

Acquisition Activity

On April 6, 2005, Bio-Rad submitted a proposal to acquire BioSource International, Inc. for $8.50 per share. The proposal was rejected by BioSource's Board on April 11, 2005. Bio-Rad currently owns 6.8% of BioSource and may pursue the acquisition in the future.

Legal Proceedings and Contingencies

Applera/Roche Litigation: A jury awarded Applera and Roche $35.4 million in damages for patent infringement related to PCR technology (MJ Research acquisition). The court granted a motion for enhancement of damages on March 30, 2005. Bio-Rad has posted a $37.2 million surety bond to stay enforcement pending appeal. The company has established a $50.0 million litigation accrual. Bio-Rad is also involved in related patent disputes in Germany and Japan, though some injunctions have been lifted following patent revocations.

Accounting Changes

The company is required to adopt SFAS 123(R) regarding share-based payments effective January 1, 2006. Pro forma net income for Q1 2005 would have been $32.6 million (vs. reported $33.5 million) if stock-based compensation had been expensed under fair value methods.

Investor Verification Checklist

• Legal Exposure: Verify the status of the $35.4 million patent infringement judgment against MJ Research and the potential for additional attorney fees or interest.
• Acquisition Status: Monitor the outcome of the rejected BioSource International acquisition proposal and any future strategic moves.
• Debt Servicing: Review the impact of the new $200 million 6.125% Notes and $225 million 7.5% Notes on future interest expenses and cash flow.
• Segment Margins: Assess the sustainability of Life Science margins given the decline in BSE test pricing and the mix shift toward lower-margin instruments.
• Stock-Based Compensation: Evaluate the impact of the upcoming SFAS 123(R) adoption on 2006 earnings.